Lazard Asset Management
LGND icon

Lazard Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Lazard Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.21M Buy
+19,659
New +$4.63M 0.01% 555
2025
Q2 		– Sell
-435
Closed -$45K – 2429
2025
Q1 		$45K Sell
435
-224
-34% -$25.3K ﹤0.01% 2014
2024
Q4 		$70K Sell
659
-1,507
-70% -$170K ﹤0.01% 1909
2024
Q3 		$216K Hold
2,166
– – ﹤0.01% 1592
2024
Q2 		$181K Buy
2,166
+981
+83% +$78.1K ﹤0.01% 1591
2024
Q1 		$86K Hold
1,185
– – ﹤0.01% 1587
2023
Q4 		$84K Hold
1,185
– – ﹤0.01% 1728
2023
Q3 		$71K Buy
1,185
+641
+118% +$42.2K ﹤0.01% 1752
2023
Q2 		$39K Buy
+544
New +$40.8K ﹤0.01% 1908
2023
Q1 		– Sell
-7,269
Closed -$485K – 2441
2022
Q4 		$485K Sell
7,269
-4,383
-38% -$285K ﹤0.01% 1131
2022
Q3 		$625K Buy
11,652
+10,232
+721% +$601K ﹤0.01% 1064
2022
Q2 		$79K Hold
1,420
– – ﹤0.01% 1604
2022
Q1 		$99K Buy
1,420
+30
+2% +$2.18K ﹤0.01% 1405
2021
Q4 		$133K Buy
1,390
+104
+8% +$9.61K ﹤0.01% 1362
2021
Q3 		$111K Sell
1,286
-115
-8% -$8.89K ﹤0.01% 1391
2021
Q2 		$114K Buy
1,401
+16
+1% +$1.33K ﹤0.01% 1311
2021
Q1 		$131K Hold
1,385
– – ﹤0.01% 1163
2020
Q4 		$85K Buy
+1,385
New +$79K ﹤0.01% 1222
2019
Q4 		– Sell
-8,735
Closed -$542K – 1602
2019
Q3 		$542K Buy
8,735
+5,109
+141% +$321K ﹤0.01% 814
2019
Q2 		$258K Sell
3,626
-2,106
-37% -$155K ﹤0.01% 1000
2019
Q1 		$449K Buy
5,732
+4,063
+243% +$308K ﹤0.01% 932
2018
Q4 		$141K Buy
+1,669
New +$178K ﹤0.01% 889
2014
Q4 		– Sell
-29,583
Closed -$867K – 1151
2014
Q3 		$867K Buy
+29,583
New +$982K ﹤0.01% 696

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's LGND Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 19,659 shares worth $6.21M. The stake represents 0.01% of the portfolio and ranks #555 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in LGND as recently as Q1 2025.

Lazard Asset Management first reported a position in LGND in Q3 2014 and has held it in 23 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Lazard Asset Management held 19,659 shares of Ligand Pharmaceuticals worth $6.21M as of Q2 2026.
  • Ligand Pharmaceuticals was a new Lazard Asset Management position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #555 holding.
  • Lazard Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 23 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.